DE10303584A1 - Erythropoietin is applied as a coating material to medical implants to improve the acceptance behavior of relevant body tissues - Google Patents
Erythropoietin is applied as a coating material to medical implants to improve the acceptance behavior of relevant body tissues Download PDFInfo
- Publication number
- DE10303584A1 DE10303584A1 DE2003103584 DE10303584A DE10303584A1 DE 10303584 A1 DE10303584 A1 DE 10303584A1 DE 2003103584 DE2003103584 DE 2003103584 DE 10303584 A DE10303584 A DE 10303584A DE 10303584 A1 DE10303584 A1 DE 10303584A1
- Authority
- DE
- Germany
- Prior art keywords
- erythropoietin
- medical implants
- coating material
- improve
- body tissues
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/28—Materials for coating prostheses
- A61L27/34—Macromolecular materials
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Medicinal Chemistry (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Materials For Medical Uses (AREA)
Abstract
Description
In der Medizin ist der Einsatz von Erythropoietin (EPO) für eine verstärkte Erzeugung von Erythrozyten bekannt. Bekannt ist auch eine antiapoptotische (programmierter Zelltod), eine angiogenetische (Gefäßneubildung) und entzündungshemmende Wirkung. Die Applikation kann intravenös oder subkutan erfolgen.In medicine, the use of Erythropoietin (EPO) for a reinforced one Generation of erythrocytes known. An anti-apoptotic is also known (programmed cell death), angiogenic (new vascularization) and anti-inflammatory Effect. It can be administered intravenously or subcutaneously.
Bekannt ist es auch, dass das Maß des im Implantationsumfeld vorhandenen Blutgerinnsels (Blutkoagulum) das Rezeptionsverhalten des betreffenden Implantats bestimmt. Dies geschieht über eine verstärkte Gefäß- und nachfolgende Knochenneubildung.It is also known that the measure of the implantation environment existing blood clot (blood coagulum) the reception behavior of the implant in question. This is done via a increased Vascular and subsequent New bone formation.
Erfindungsgemäß ist festgestellt worden, dass das Rezeptionsverhalten, das heißt die Knochenregeneration im Implantationsgrenz- und umfeld durch eine ausschließliche oder zusätzliche Applikation des EPO direkt auf das Implantat in der Form einer Beschichtung noch erheblich über das bisher bekannte Maß hinaus verbessert werden kann.According to the invention, it has been found that the reception behavior, i.e. the bone regeneration in the implantation limit and environment by an exclusive or additional Application of the EPO directly on the implant in the form of a coating still significantly over the previously known dimension can be improved.
Die Beschichtung kann in einer besonders vorteilhaften Weise erzeugt werden an der Implantatoberfläche durch eine kovalente Bindung von Kollagen mit Kohlenhydraten/Sialinsäure. Wichtig für eine erfindungsgemäß gute Wirkung ist die Erzielung einer möglichst hohen lokalen EPO-Konzentration in der aufgebrachten Schicht. Das Erythropoietin soll über einen möglichst langen Zeitraum an das umliegende Gewebe abgegeben werden und lokal zu hohen Konzentrationen an Erythropoietin im umliegenden Gewebe beitragen.The coating can be particularly advantageous Be generated on the implant surface by a covalent bond of collagen with carbohydrates / sialic acid. Important for a good effect according to the invention is achieving one if possible high local EPO concentration in the applied layer. The Erythropoietin is said to be about one if possible long period of time to the surrounding tissue and locally too high concentrations of erythropoietin in the surrounding tissue contribute.
Die zu beschichtenden Implantate können insbesondere aus Titan, Aluminiumoxid oder Keramik bestehen oder auch abbaubare (Kollagene), nicht abbaubare Membrane (Gore-Tex®), Membrane aus Titan sein, wie sie beispielsweise in der Zahnmedizin und Chirurgie zur kontrollierten Knochenregeneration eingesetzt werden.The implants to be coated can be made in particular of titanium, aluminum oxide or ceramic, or they can also be degradable (collagens), non-degradable membranes (Gore- Tex® ), membranes made of titanium, such as those used in dentistry and surgery for controlled bone regeneration.
Besonders vorteilhaft können erfindungsgemäß beschichtete Implantate in der Zahnmedizin und Chirurgie eingesetzt werden.Coated according to the invention can be particularly advantageous Implants can be used in dentistry and surgery.
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE2003103584 DE10303584A1 (en) | 2003-01-30 | 2003-01-30 | Erythropoietin is applied as a coating material to medical implants to improve the acceptance behavior of relevant body tissues |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE2003103584 DE10303584A1 (en) | 2003-01-30 | 2003-01-30 | Erythropoietin is applied as a coating material to medical implants to improve the acceptance behavior of relevant body tissues |
Publications (1)
Publication Number | Publication Date |
---|---|
DE10303584A1 true DE10303584A1 (en) | 2004-08-12 |
Family
ID=32695041
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE2003103584 Withdrawn DE10303584A1 (en) | 2003-01-30 | 2003-01-30 | Erythropoietin is applied as a coating material to medical implants to improve the acceptance behavior of relevant body tissues |
Country Status (1)
Country | Link |
---|---|
DE (1) | DE10303584A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1699915A1 (en) * | 2003-12-30 | 2006-09-13 | Bionethos Holding Gmbh | Tissue regeneration method |
JP2011510066A (en) * | 2008-01-24 | 2011-03-31 | レメドー バイオメッド リミテッド | Erythropoietin and fibronectin composition for bone regeneration |
US10792338B2 (en) | 2007-08-16 | 2020-10-06 | Remedor Biomed Ltd. | Erythropoietin and fibronectin compositions for therapeutic and cosmetic applications |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994001483A1 (en) * | 1992-07-02 | 1994-01-20 | Collagen Corporation | Biocompatible polymer conjugates |
WO2001040272A2 (en) * | 1999-12-01 | 2001-06-07 | Selective Genetics, Inc. | In situ bioreactors and methods of use thereof |
WO2001074413A1 (en) * | 2000-04-04 | 2001-10-11 | Boston Scientific Limited | Medical devices suitable for gene therapy regimens |
US20020160033A1 (en) * | 2001-04-25 | 2002-10-31 | Noel Caplice | Implantable medical devices |
DE69714448T2 (en) * | 1996-05-14 | 2002-11-14 | Alkermes Controlled Therapeutics, Inc. | METHOD FOR PRODUCING PREPARATIONS WITH CONTROLLED ACTIVE SUBSTANCE RELEASE BASED ON POLYMERS |
WO2002098475A1 (en) * | 2001-06-06 | 2002-12-12 | Smith & Nephew Plc | Fixation devices for tissue repair |
DE69332222T2 (en) * | 1992-06-11 | 2003-03-20 | Alkermes Inc | ENYTHROPOIETIN CONTAINING DRUG DISPENSING SYSTEM |
-
2003
- 2003-01-30 DE DE2003103584 patent/DE10303584A1/en not_active Withdrawn
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69332222T2 (en) * | 1992-06-11 | 2003-03-20 | Alkermes Inc | ENYTHROPOIETIN CONTAINING DRUG DISPENSING SYSTEM |
WO1994001483A1 (en) * | 1992-07-02 | 1994-01-20 | Collagen Corporation | Biocompatible polymer conjugates |
DE69714448T2 (en) * | 1996-05-14 | 2002-11-14 | Alkermes Controlled Therapeutics, Inc. | METHOD FOR PRODUCING PREPARATIONS WITH CONTROLLED ACTIVE SUBSTANCE RELEASE BASED ON POLYMERS |
WO2001040272A2 (en) * | 1999-12-01 | 2001-06-07 | Selective Genetics, Inc. | In situ bioreactors and methods of use thereof |
WO2001074413A1 (en) * | 2000-04-04 | 2001-10-11 | Boston Scientific Limited | Medical devices suitable for gene therapy regimens |
US20020160033A1 (en) * | 2001-04-25 | 2002-10-31 | Noel Caplice | Implantable medical devices |
WO2002098475A1 (en) * | 2001-06-06 | 2002-12-12 | Smith & Nephew Plc | Fixation devices for tissue repair |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1699915A1 (en) * | 2003-12-30 | 2006-09-13 | Bionethos Holding Gmbh | Tissue regeneration method |
US10792338B2 (en) | 2007-08-16 | 2020-10-06 | Remedor Biomed Ltd. | Erythropoietin and fibronectin compositions for therapeutic and cosmetic applications |
JP2011510066A (en) * | 2008-01-24 | 2011-03-31 | レメドー バイオメッド リミテッド | Erythropoietin and fibronectin composition for bone regeneration |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Balamurugan et al. | Corrosion aspects of metallic implants—An overview | |
Comuzzi et al. | Injectable calcium phosphate cement as a filler for bone defects around oral implants: an experimental study in goats | |
Small et al. | A sixteen-year evaluation of the mandibular staple bone plate | |
JPH08505559A (en) | Bone fusion promoting implant composition, implant assembly and implant implantation method | |
Drugacz et al. | Use of TiNiCo shape-memory clamps in the surgical treatment of mandibular fractures | |
Datta et al. | Advanced materials in biological implants and surgical tools | |
Bai et al. | Microarc oxidation coating covered Ti implants with micro-scale gouges formed by a multi-step treatment for improving osseointegration | |
Che Lah et al. | Titanium and Titanium Based Alloys as Metallic Biomaterials in Medical Applications-Spine Implant Case Study. | |
Torkzaban et al. | Efficacy of application of platelet-rich fibrin for improvement of implant stability: a clinical trial | |
Rudy et al. | Intraosseous anchorage of dental prostheses: an early 20th century contribution | |
RU2399387C2 (en) | Implantation and parodentium plasty material and method for making thereof | |
Awati et al. | Limitations of current metallic bone plates: towards development of composite bone plates | |
DE10303584A1 (en) | Erythropoietin is applied as a coating material to medical implants to improve the acceptance behavior of relevant body tissues | |
Nocini et al. | Simultaneous bimaxillary alveolar ridge augmentation by a single free fibular transfer: a case report | |
Majzoub et al. | Guided bone regeneration using demineralized laminar bone sheets versus GTAM membranes in the treatment of implant‐associated defects. A clinical and histological study. | |
RU2397732C2 (en) | Dental ventplant and material with shape memory for its production | |
Parthasarathy et al. | VOLUMETRIC CBCT EVALAUTION OF STICKY BONE (ABBM+ i-PRF) IN HORIZONTAL RIDGE AUGMENTATION-A CASE SERIES | |
Sharma et al. | Biomaterials and their applications | |
Fanali et al. | Effect of distance between one piece implants on crestal bone resorption | |
JP6185679B1 (en) | Chromium-modified implant and method for producing the same | |
Fahmy et al. | Materials Used Intraoperatively During Oral and Maxillofacial Surgery Procedures | |
Khalfaoui et al. | Closure of oroantral communication with platelet-rich fibrin: A case report | |
O'Fearraigh | Review of methods used in the reconstruction and rehabilitation of the maxillofacial region. | |
Raghavan et al. | Titanium toxicity—A review | |
RU2696044C1 (en) | Alveolar bone plasty method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
OM8 | Search report available as to paragraph 43 lit. 1 sentence 1 patent law | ||
8139 | Disposal/non-payment of the annual fee |